Mid-Size CRO Offers Flexibility Collaboration and AI Tools to Transform Clinical Trials with Dr. Philip Räth Palleos Healthcare TRANSCRIPT
Download PDFNov 19, 2024
Dr. Philip Räth, Managing Director at Palleos, discusses the advantages of a mid-size contract research organization compared to a large CRO. Customized solutions, strong cross-departmental cooperation, and fast decision-making are key to addressing the most significant unmet needs of clinical trial sponsors. This nimble clinical trial model, supported by machine learning, emphasizes collaboration and transparency.
Philip explains, "In the end, we are a service industry, so it's always about time, costs, and quality. So, certain structures have been established in terms of project management and how you set up trials. We have regulations in place that are very clear on how things should get done. So, I think what collaboration enables is getting something done together. Collaboration between sponsors and CROs can transform the landscape and situation where collaboration enables trust and, therefore, change is possible."
"I think that's always the biggest challenge for collaboration. You have change in the project, you have change in the clinical trial landscape in terms of maybe IT or information systems which become more prominent, or there are changes in regulation. So tackling these changes is mostly done through collaboration with a big foundation and trust so people can make bigger jumps and quicker decisions instead of just looking at what's on the contract regarding the deliverables."
#Palleos #ClinicalTrials #CRO #ContractResearchOrganization
